Caladrius Biosciences, Inc. (Caladrius, formerly NeoStem) is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market.
Company Growth (employees)
Allendale, US
Size (employees)
221 (est)
Caladrius was founded in 2006 and is headquartered in Allendale, US

Key People at Caladrius

Robin L. Smith

Robin L. Smith


Caladrius Office Locations

Caladrius has offices in Allendale, Mountain View
Allendale, US
Mountain View, US

Caladrius Metrics

Caladrius Summary

Market capitalization

$28.3 m

Closing share price

Caladrius's current market capitalization is $28.3 m.

Caladrius Financials

Caladrius's revenue is $14.7 m in FY, 2013 which is a 18.2% decrease from the previous period.
FY, 2013FY, 2014FY, 2015Y, 2016


$14.7 m$17.9 m$22.5 m$35.3 m

Revenue growth, %


Net Income

($39.5 m)($55.5 m)($81 m)

Caladrius Online Presence

Caladrius Company Life

You may also be interested in